The purpose of this study is to evaluate novel KarX and KarT prototypes versus the KarXT and KarX-EC reference following single doses, and to explore the effect of food after multiple doses of selected prototypes in healthy adult participants.
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Maximum observed concentration (Cmax)
Timeframe: Up to Day 23
Time of maximum observed concentration (Tmax)
Timeframe: Up to Day 23
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Timeframe: Up to Day 23
Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Timeframe: Up to Day 23
Area under the concentration-time curve in 1 dosing interval (AUC(TAU))
Timeframe: Up to Day 23
Concentration at the end of a dosing interval (Ctau)
Timeframe: Up to Day 23
Apparent total body clearance (CLT/F)
Timeframe: Up to Day 23
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Effective elimination half-life during dosing interval (T-HALF(eff))
Timeframe: Up to Day 23